Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Luminar Technologies, Inc. (“Luminar”) (NASDAQ: LAZR)

On July 23, 2025, a class action complaint alleging violations of federal securities laws was filed against Luminar in federal court on behalf of investors who acquired Luminar securities between March 20, 2025 and May 14, 2025, both dates inclusive (the “Class Period”). 

Luminar Investors May Have Legal Claims

Luminar investors who acquired their securities during the Class Period are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.  

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Replimune Group, Inc. (“Replimune”) (NASDAQ: REPL).

On July 22, 2025, Replimune announced that the FDA “. . . issued a Complete Response Letter (CRL) regarding the Biologics License Application . . . for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.”

The FDA’s CRL, according to Repliumne, “. . . indicates that the FDA is unable to approve the application in its present form. The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.”

On this news, shares of Replimune stock were down more than 76% pre-market on July 22, 2025.

Class Action Filed on Behalf of Replimune Investors

On July 24, 2025, a class action complaint alleging violations of federal securities laws was filed against Replimune in federal court on behalf of investors who acquired their securities between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”).

Replimune Investors May Have Legal Claims

Replimune investors who acquired their securities during the Class Period are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.  

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Alto Neuroscience, Inc. (“Alto Neuroscience”) (NYSE: ANRO)

On July 21, 2025, a class action complaint alleging violations of federal securities laws was filed against Alto Neuroscience in federal court on behalf of investors who acquired 1) Alto Neuroscience common stock pursuant and/or traceable to the Offering Documents issued in connection with Alto Neuroscience’s initial public offering (“IPO”) conducted on or about February 2, 2024 and/or 2) Alto Neuroscience securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”). 

Alto Neuroscience Investors May Have Legal Claims

Alto Neuroscience investors who acquired their stock or securities pursuant to the IPO or during the Class Period are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.  

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Neogen Corporation (“Neogen”) (NASDAQ: NEOG)

On July 18, 2025, a class action complaint alleging violations of federal securities laws was filed against Neogen in federal court on behalf of investors who acquired Neogen common stock between January 5, 2023 and June 3, 2025, both dates inclusive (the “Class Period”). 

Neogen Investors May Have Legal Claims

Neogen investors who acquired their stock during the Class Period are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.  

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals”) (NASDAQ: RCKT)

On July 18, 2025, a class action complaint alleging violations of federal securities laws was filed against Rocket Pharmaceuticals in federal court on behalf of investors who acquired Rocket Pharmaceuticals securities between September 17, 2024 and May 26, 2025, both dates inclusive (the “Class Period”). 

Rocket Pharmaceuticals Investors May Have Legal Claims

Investors of Rocket Pharmaceuticals who acquired their securities during the Class Period are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.  

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor”) (NASDAQ: CAPR)

On July 17, 2025, a class action complaint alleging violations of federal securities laws was filed against Capricor in federal court on behalf of investors who acquired Capricor securities between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”). 

Capricor Investors May Have Legal Claims

Capricor investors who acquired their securities during the Class Period are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.  

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]